Adventitious Virus Testing for Biologics: ICH Q5A(R2), In Vitro Assays, and NGS Methods

What Is Adventitious Virus Testing?

Adventitious virus testing is the systematic screening of cell substrates, raw materials, and biologic drug substance for unintended viral contaminants that may have been introduced during manufacturing. These viruses are distinct from endogenous retroviruses (which are inherent to the host cell genome) and are instead acquired from contaminated raw materials, operator handling, or the original tissue used to establish the cell line.

The regulatory framework for viral safety evaluation of biologics is defined by ICH Q5A(R2), which was revised in 2024 after more than two decades since the original Q5A(R1) guideline. The revision introduced NGS as an accepted methodology, eliminated the requirement for in vivo animal testing, and modernized the risk-based approach to adventitious agent testing. Every biologic product derived from human or animal cell lines requires a viral safety evaluation covering three pillars: cell substrate characterization, viral clearance validation, and adventitious agent testing of production lots.

Contamination events, while rare, carry severe consequences. The most cited historical case is the discovery of porcine circovirus type 1 (PCV1) DNA in rotavirus vaccines (RotaTeq and Rotarix) in 2010, detected only after NGS technology became available. Earlier incidents include vesivirus 2117 contamination at Genzyme in 2009, which shut down the Allston, MA manufacturing facility and disrupted supply of Cerezyme and Fabrazyme, affecting approximately 8,000 patients with Gaucher and Fabry disease at an estimated cost of $200-300 million. These events drove the industry toward broader detection methods and the eventual acceptance of NGS in the regulatory framework.

ICH Q5A(R2) Requirements and Testing Strategy

ICH Q5A(R2) replaced the original 1999 Q5A(R1) guideline and took effect in 2024 across FDA, EMA, and PMDA jurisdictions. The revision made three landmark changes: formal acceptance of NGS as a testing methodology, elimination of the requirement for in vivo animal testing (suckling mice, adult mice, guinea pigs, and embryonated eggs), and a more explicit risk-based framework for determining testing scope.

The guideline applies to all products derived from characterized cell banks of human or animal origin. This includes monoclonal antibodies from CHO, HEK293, NS0, and Sp2/0 cell lines, viral vectors (AAV, lentivirus) from HEK293 and Sf9/Hi5 insect cells, recombinant proteins, and cell and gene therapy products. The scope explicitly excludes products derived from primary cell cultures and tissues, which fall under separate guidance.

The risk-based approach considers three factors when determining testing scope:

• Cell line origin — rodent-derived lines (CHO, NS0, BHK) carry endogenous retrovirus risk; human-derived lines (HEK293) carry risk for human-tropic viruses; insect cell lines (Sf9) carry lower mammalian virus risk
• Raw materials — bovine serum use introduces BVDV, BPV, and BSE risk; porcine trypsin introduces PPV and PCV risk; human-derived supplements may carry B19, HIV, HBV, HCV risk
• Process history — passage number, manufacturing facility controls, prior contamination events

In Vitro Cell-Based Assays: Indicator Cell Lines and Detection Methods

In vitro adventitious virus assays remain the workhorse of broad-spectrum viral detection for biologics. The assay uses multiple indicator cell lines that are permissive to a wide range of viruses, and detects contamination through three complementary readouts: cytopathic effect (CPE), hemadsorption (HAd), and hemagglutination (HA).

ICH Q5A(R2) requires testing on at least three indicator cell lines:

• Human diploid cell line (MRC-5 or WI-38) — detects human-tropic viruses including adenoviruses, herpesviruses, enteroviruses, and paramyxoviruses
• Monkey kidney cell line (Vero, primary African green monkey kidney, or CV-1) — detects a broad spectrum of mammalian viruses and is particularly sensitive to SV40, orthopoxviruses, and arboviruses
• Same-species cell line — a cell line of the same species and tissue type as the production cell (e.g., a non-producing CHO line for CHO-derived products) to detect viruses that require species-specific receptors

The assay procedure involves inoculating each indicator cell culture with the test article (lysate for cell bank testing, unprocessed harvest for lot testing), incubating for 14-28 days with regular microscopic observation for cytopathic effects, then performing endpoint hemadsorption using guinea pig and human type O erythrocytes to detect non-cytopathic agents such as influenza, parainfluenza, and mumps viruses. Positive and negative controls (including a spiked control demonstrating the assay can detect a model virus in the test matrix) are run in parallel.

The limit of detection for in vitro assays is approximately 1-10 infectious units per millilitre, depending on the virus and cell line combination. The primary limitation is that the assay only detects viruses that can replicate in the chosen indicator cell lines and produce detectable CPE or hemadsorption. Non-cytopathic, non-hemadsorbing viruses (such as certain retroviruses, hepatitis viruses, and novel agents) may escape detection entirely.

Species-Specific PCR Panels

Species-specific PCR panels complement in vitro assays by targeting known viral contaminants associated with the production cell line species and raw materials. Unlike in vitro assays, PCR detects viral nucleic acid directly and does not require the virus to be replication-competent in an indicator cell line.

For CHO-derived products (the most common platform for monoclonal antibodies), the standard murine/hamster virus panel typically includes 9-12 targets:

For HEK293-derived products (AAV vectors, lentiviral vectors), the human virus panel typically includes HIV-1/2, HTLV-1/2, HBV, HCV, CMV, EBV, HHV-6, HHV-8, parvovirus B19, and adeno-associated virus (AAV, endogenous). If bovine serum was used in cell bank establishment, a bovine virus panel (BVDV, BPV, bovine adenovirus, bovine parvovirus, bovine reovirus, rabies, parainfluenza 3) is added. If porcine trypsin was used, porcine parvovirus (PPV) and porcine circovirus (PCV) testing is required.

NGS Metagenomics for Adventitious Agent Detection

Next-generation sequencing has transformed adventitious virus testing by enabling unbiased, sequence-independent detection of viral nucleic acids. Unlike in vitro assays (which require viral replication) or PCR (which requires prior knowledge of target sequences), NGS can detect any virus with a DNA or RNA genome, including novel, divergent, or unexpected agents.

The typical NGS workflow for adventitious agent testing involves:

1. Sample preparation — nuclease treatment to remove free host nucleic acids (DNase/RNase), followed by viral particle enrichment via filtration (0.2-0.45 μm) or ultracentrifugation
2. Nucleic acid extraction — total nucleic acid extraction from enriched particles, with separate RNA and DNA library preparation workflows
3. Library preparation — random priming and cDNA synthesis (for RNA viruses), followed by adapter ligation and amplification
4. Sequencing — Illumina short-read (150-300 bp paired-end, 10-50 million reads) or Oxford Nanopore long-read sequencing
5. Bioinformatics — host genome subtraction (removes >99% of reads), de novo assembly of remaining reads, taxonomic classification against comprehensive viral databases (NCBI RefSeq, UniProt, RVDB), and reporting

The sensitivity of NGS depends on sequencing depth and sample preparation. With adequate enrichment and 20-50 million total reads, detection limits of 1-10 viral copies per millilitre have been demonstrated for both DNA and RNA viruses. Turnaround time is 5-10 working days from sample receipt to final report, compared to 28 days for in vitro assays.

The 2024 revision of ICH Q5A formally accepts NGS as a replacement for in vivo assays at all testing stages. It also recognizes NGS as a complementary method alongside in vitro assays, with several regulatory authorities now accepting NGS data as primary evidence in BLA/MAA submissions. Full replacement of in vitro assays by NGS alone is under active regulatory discussion, with multiple companies having filed successfully using NGS as the primary broad-spectrum detection method at the cell bank characterization stage.

The key limitation of NGS is that it detects nucleic acid, not infectious virus. A positive NGS finding requires follow-up with infectivity assays to determine whether the detected sequence represents viable, replication-competent virus or residual nucleic acid. This distinction is critical for risk assessment and regulatory decision-making.

When Is Adventitious Virus Testing Required?

ICH Q5A(R2) defines four manufacturing stages at which adventitious virus testing is required, each with a different scope of testing. The testing intensity is highest at cell bank characterization (performed once) and lowest at production lot testing (performed for every batch).

Master Cell Bank (MCB) characterization represents the most comprehensive testing point. This is a one-time evaluation performed when the cell bank is first established. It includes the full in vitro assay panel on three indicator cell lines, the complete species-specific PCR panel, retrovirus testing using both the product-enhanced reverse transcriptase (PERT) assay and quantitative PCR for retroviral sequences, thin-section transmission electron microscopy (TEM) to visualize retrovirus-like particles and other intracellular agents, and increasingly NGS metagenomics. The viral safety portion of the MCB characterization typically costs $80,000-$120,000 and takes 3-6 months to complete (the full MCB characterization package including identity, purity, karyology, and other tests runs $150,000-$300,000).

End-of-production cells (EPC) testing is performed on cells that have been passaged to the limit of in vitro cell age used in manufacturing. This confirms that no latent virus has been activated or amplified during the extended culture period. The testing panel mirrors the MCB characterization scope. If the production process includes a maximum in vitro cell age of passage 45, the EPC cells should be at or beyond passage 45.

Unprocessed bulk harvest testing is performed on every production lot before the material enters downstream purification. The minimum requirement is an in vitro assay (14-day observation) on appropriate indicator cell lines. For products derived from rodent cell lines, a PCR or qPCR assay for murine retroviruses is also required on every lot. This per-lot testing is the final safety gate before product enters the purification process.

Detection Method Comparison: Sensitivity, Breadth, and Cost

The five primary detection methods for adventitious virus testing each offer different trade-offs in sensitivity, detection breadth, turnaround time, and cost. No single method is sufficient alone, which is why ICH Q5A(R2) requires a combination approach.

Figure 2. Comparison of five adventitious virus detection methods across four performance dimensions. Each bar represents the method's relative score (1-10 scale) for sensitivity, breadth of detection, speed, and cost-effectiveness.

Figure 3. Testing scope at each manufacturing stage per ICH Q5A(R2). MCB and EPC require the most comprehensive panels. Unprocessed bulk requires per-lot in vitro testing and retrovirus PCR. WCB testing is reduced based on risk assessment.

Worked Example: CHO mAb Viral Safety Testing Strategy

Frequently Asked Questions

Related Tools

• Viral Clearance LRV Calculator — Build multi-step viral clearance strategies and calculate cumulative log reduction values against ICH Q5A thresholds.
• Cell Bank Calculator — Plan MCB/WCB cell bank inventory, passage tracking, and qualification timelines.
• Clone Scorecard — Rank and compare production clones across productivity, stability, and quality attributes.

References

1. ICH Q5A(R2). Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. International Council for Harmonisation. 2024. ich.org
2. Khan A.S. et al. Report of the Fourth Conference on Next-Generation Sequencing (NGS) for Adventitious Virus Detection in Biologics for Humans and Animals: Validation and Implementation of NGS. Biologicals. 2025;89:101859. doi:10.1016/j.biologicals.2025.101859
3. Charlebois R.L. et al. Sensitivity and Breadth of Detection of High-Throughput Sequencing for Adventitious Virus Detection. npj Vaccines. 2020;5:61. doi:10.1038/s41541-020-0207-4
4. Gombold J. et al. Systematic Evaluation of In Vitro and In Vivo Adventitious Virus Assays for the Detection of Viral Contamination of Cell Banks and Biological Products. Vaccine. 2014;32(24):2916-2926. doi:10.1016/j.vaccine.2014.02.021
5. Onions D. et al. Validation of the Safety of MDCK Cells as a Substrate for the Production of a Cell-Derived Influenza Vaccine. Biologicals. 2010;38(5):544-551. doi:10.1016/j.biologicals.2010.04.003